Institutions · Entity Annotation Prototype (beta)

1articles mentioning institutions

1institution mentions

1distinct institutions extracted

0%of mentions human-reviewed

Active filtersEntity: KEYNOTE-522 trial ×

KEYNOTE-522 trial

This institution is selected. Its supporting articles are shown below.

KEYNOTE-522 trial1

Articles mentioning KEYNOTE-522 trial

1 articles · page 1 of 1

Pembrolizumab-induced lipodystrophy following pathological complete response in triple-negative breast cancer

bmjcr · abstract · 2026-01-29 · 1 matching annotations

80.5%

KEYNOTE-522 trial pembrolizumab Triple-negative breast cancer neoadjuvant chemotherapy Corticosteroids TNBC neoadjuvant chemoimmunotherapy

… (TNBC) is an aggressive subtype with high recurrence risk. The KEYNOTE-522 trial demonstrated improved pathological complete response (pCR) rate…

Browse institutions

KEYNOTE-522 trial

Articles mentioning KEYNOTE-522 trial

Pembrolizumab-induced lipodystrophy following pathological complete response in triple-negative breast cancer